Google
LIXT — LIXTE BIOTECHNOLOGY HOLDINGS INC (Healthcare >> Biotechnology)
LIXT FAQ
What is LIXT's ROE?
LIXTE BIOTECHNOLOGY HOLDINGS INC reports a Return on Equity (ROE) of -91.55%.
What is LIXT's dividend yield?
LIXTE BIOTECHNOLOGY HOLDINGS INC offers a dividend yield of 0.00%.
What is LIXT's Deepscope Quality Score?
Deepscope rates LIXT's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy LIXT?
Deepscope's AI Timing Score for LIXT is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does LIXT belong to?
LIXTE BIOTECHNOLOGY HOLDINGS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 6.71
Price
-0.33
(-4.69%)
Day Change
|
|
|---|
LIXT Chất lượng tổng thể của cố phiếu Không tốt ( Chất lượng = 38) nhưng Thời điểm mua ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
Tỷ lệ ROE tương đối thấp
Tỷ lệ ROA tương đối thấp
Lịch sử ROE tương đối thấp
ROE đang giảm đáng kể
ROA quá thấp so với ROE
Tăng trưởng ROA hiện tại đang dưới mức tiêu chí của chúng tôi.
Biên lợi nhuận ròng tương đối thấp.
Tốc độ tăng trưởng biên lợi nhuận ròng dưới mức tiêu chí của chúng tôi
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
Chi tiết hơn, sẽ thấy rằng các yếu tố chất lượng Không tốt , Sức khỏe tài chính Không tốt lắm , và khả năng kiếm lợi nhuận Không tốt , ...
| Yếu tố Chất lượng |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 66 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 6.71 |
| PBV / Sector |
9.50 / 4.48
|
| Earning Per Share | -0.56 |
| PE / Sector |
N/A / 16.68
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
0.99 M
GREAT
|
| Average 1W Daily Value |
2.08 M
GREAT
|
| Yếu tố Kỹ thuật |
|
57% |
| Sức khỏe tài chính |
|
50% |
| Khả năng kiếm lợi nhuận |
|
37% |
| Lợi tức cho nhà đầu tư |
|
4% |
| Chi tiết đăng ký |
| Analyze Date | 2026-06-04 09:24:16 |
| Symbol | LIXT |
| Name | LIXTE BIOTECHNOLOGY HOLDINGS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 12.38 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 87.18 / 8,483.11 |
| Tin tức, Dự báo ước tính |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 433 Plaza Real, Boca Raton, FL, United States, 33432
Phone: 631 830 7092
Website: https://lixte.com
Sector: Healthcare >> Biotechnology
Description: Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical and proton cancer therapy company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Boca Raton, Florida.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
